Dulaglutide

Overview

Dulaglutide (brand name Trulicity) is a long-acting GLP-1 receptor agonist fusion protein developed by Eli Lilly. It was approved by the FDA in September 2014 for glycemic control in type 2 diabetes, and gained a second approval in February 2020 for reducing major adverse cardiovascular events in type 2 diabetes patients with established cardiovascular disease or multiple cardiovascular risk factors. Vialdyne releases Dulaglutide as a lyophilized peptide against a ≥95% (SEC/RP-HPLC) HPLC main-peak specification, supplied with a batch-specific Certificate of Analysis covering RP-HPLC purity, mass-spec identity, appearance, and water content. Lots are released only after the COA is on file.

Applications & buyer fit

Most buyers in this category are 503A and 503B compounding pharmacies fulfilling metabolic and weight-management protocols, plus research labs investigating GLP-1 / GIP / GCG receptor pharmacology. The procurement decision usually hinges on three things: documented purity at scale, a regulatory team that can respond on destination-market questions in writing, and the ability to supply consistent counter-ion form (acetate by default) across recurring orders.

Primary buyer fit: academic and contract research laboratories.

Specifications

CAS

923950-08-7

Molecular Weight

~59.7 kDa

Appearance

Clear, colorless liquid

Purity (HPLC)

≥ 95% (SEC/RP-HPLC)

Strength

5 mg – 10 mg

Packaging

10 vials/box · base pack (multiples of 10)

Half-life

≈ 5 days

MOQ

On request

Lead time

10–18 days

Storage

2–8°C, protect from light

Certificate of Analysis

Representative COA previews for Dulaglutide; request the certificate matched to the offered or supplied lot from sales. These are previews — request the full high-resolution certificate for any lot.

VerifiedRequest full COA →

Dulaglutide

VD260428-DUL067 · 99.56%

VerifiedRequest full COA →

Dulaglutide

VD260428-DUL066 · 99.66%

Regulatory note

Research-use-only reference material; not for human or veterinary use.

Selected literature

1. Gerstein HC, Colhoun HM, Dagenais GR, et al. Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial. Lancet. 2019;394(10193):121-130.
2. Jendle J, Grunberger G, Blevins T, Giorgino F, Hietpas RT, Botros FT. Efficacy and safety of dulaglutide in the treatment of type 2 diabetes: a comprehensive review of the dulaglutide clinical data focusing on the AWARD phase 3 clinical trial program. Diabetes Metab Res Rev. 2016;32(8):776-790.
3. Frias JP, Bonora E, Nevarez Ruiz L, et al. Efficacy and Safety of Dulaglutide 3.0 mg and 4.5 mg Versus Dulaglutide 1.5 mg in Metformin-Treated Patients With Type 2 Diabetes in a Randomized Controlled Trial (AWARD-11). Diabetes Care. 2021;44(3):765-773.
4. Jimenez-Solem E, Rasmussen MH, Christensen M, Knop FK. Dulaglutide, a long-acting GLP-1 analog fused with an Fc antibody fragment for the potential treatment of type 2 diabetes. Curr Opin Mol Ther. 2010;12(6):790-797.
5. Zhang L, Zhang M, Zhang Y, Tong N. Efficacy and safety of dulaglutide in patients with type 2 diabetes: a meta-analysis and systematic review. Sci Rep. 2016;6:18904.
6. Fala L. Trulicity (Dulaglutide): A New GLP-1 Receptor Agonist Once-Weekly Subcutaneous Injection Approved for the Treatment of Patients with Type 2 Diabetes. Am Health Drug Benefits. 2015;8(Spec Feature):131-134.

Frequently asked questions